The abstract is read at the publisher; the summary is JClub's.
Baloxavir monotherapy in cyclophosphamide-immunosuppressed hamsters infected with a human-derived influenza A(H5N1) clade 2.3.4.4b genotype D1.1 isolate achieved 100% survival and prevented neuroinvasion.
- Why it matters: Immunocompromised patients can develop severe, prolonged influenza, but evidence for antiviral therapy against highly pathogenic H5N1 in this setting is limited.
- What they did: Hamsters were infected with the British Columbia human isolate and assessed for pathogenesis and direct-contact transmission; antiviral efficacy tested oseltamivir, baloxavir, and molnupiravir (50 or 200 mg/kg twice daily) alone or with oseltamivir.
- The result: Placebo-treated animals had 50% mortality, while baloxavir reduced viral shedding, viral replication, and pulmonary inflammation; high-dose molnupiravir prevented mortality and cleared virus in lung and brain, and oseltamivir yielded 75% survival without reducing tissue viral titers.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.